Shang-yi B. Huang
1Division Of Hematology, No.7, Chung Shan S. Rd
Zhongzheng Dist, TPQ 10002, Taiwan
Zhongzheng Dist, TPQ 10002, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Consensus-based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: March 25, 2026
Real-world multicenter study of thalidomide in NDMM patients in Taiwan.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: July 03, 2025
Transglutaminase 2-mediated glutamine deamidation enhances p21 stability during senescence.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 11, 2025
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
Journal: Future oncology (London, England)
Published: January 24, 2025
Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST).
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: September 01, 2024
Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan.
Journal: Hematology (Amsterdam, Netherlands)
Published: July 03, 2024
Dynamic changes in γδT cells and bone resorption markers after zoledronic acid in multiple myeloma: A prospective study.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 21, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Journal: European journal of haematology
Published: March 29, 2024
A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia.
Journal: Heliyon
Published: November 15, 2023
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Journal: Haematologica
Published: October 04, 2023
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Journal: Haematologica
Published: September 19, 2023
Last Updated: 09/26/2026